Shanghai Pharmaceuticals ... (SHPMY)
Shanghai Pharmaceuticals Ltd Statistics
Share Statistics
Shanghai Pharmaceuticals Ltd has 1.21B shares outstanding. The number of shares has increased by -81.74% in one year.
| Shares Outstanding | 1.21B |
| Shares Change (YoY) | -81.74% |
| Shares Change (QoQ) | -80% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.82B |
| Failed to Deliver (FTD) Shares | 1.2K |
| FTD / Avg. Volume | 44.76% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 9.91 and the forward PE ratio is null. Shanghai Pharmaceuticals Ltd's PEG ratio is 0.48.
| PE Ratio | 9.91 |
| Forward PE | n/a |
| PS Ratio | 0.16 |
| Forward PS | n/a |
| PB Ratio | 0.63 |
| P/FCF Ratio | 13.16 |
| PEG Ratio | 0.48 |
Enterprise Valuation
Shanghai Pharmaceuticals Ltd has an Enterprise Value (EV) of 237.55B.
| EV / Sales | 0.86 |
| EV / EBITDA | 19.32 |
| EV / EBIT | 40.77 |
| EV / FCF | 69.33 |
Financial Position
The company has a current ratio of 1.36, with a Debt / Equity ratio of 0.67.
| Current Ratio | 1.36 |
| Quick Ratio | 1.05 |
| Debt / Equity | 0.67 |
| Debt / EBITDA | 3.89 |
| Debt / FCF | 13.95 |
| Interest Coverage | 4.38 |
Financial Efficiency
Return on Equity is 6.35% and Return on Invested Capital is 4.47%.
| Return on Equity | 6.35% |
| Return on Assets | 2.06% |
| Return on Invested Capital | 4.47% |
| Revenue Per Employee | $5.57M |
| Profits Per Employee | $92.15K |
| Employee Count | 49,402 |
| Asset Turnover | 1.24 |
| Inventory Turnover | 6.28 |
Taxes
| Income Tax | 2.15B |
| Effective Tax Rate | 26.81% |
Stock Price Statistics
The stock price has increased by -4.87% in the last 52 weeks. The beta is 0.4, so Shanghai Pharmaceuticals Ltd's price volatility has been higher than the market average.
| Beta | 0.4 |
| 52-Week Price Change | -4.87% |
| 50-Day Moving Average | 7.45 |
| 200-Day Moving Average | 7.65 |
| Relative Strength Index (RSI) | 28.67 |
| Average Volume (20 Days) | 2.67K |
Income Statement
In the last 12 months, Shanghai Pharmaceuticals Ltd had revenue of 275.25B and earned 4.55B in profits. Earnings per share was 6.15.
| Revenue | 275.25B |
| Gross Profit | 30.63B |
| Operating Income | 8.14B |
| Net Income | 4.55B |
| EBITDA | 12.3B |
| EBIT | 9.88B |
| Earnings Per Share (EPS) | 6.15 |
Balance Sheet
The company has 35.74B in cash and 47.79B in debt, giving a net cash position of -12.05B.
| Cash & Cash Equivalents | 35.74B |
| Total Debt | 47.79B |
| Net Cash | -12.05B |
| Retained Earnings | 36.55B |
| Total Assets | 221.21B |
| Working Capital | 45.78B |
Cash Flow
In the last 12 months, operating cash flow was 5.83B and capital expenditures -2.4B, giving a free cash flow of 3.43B.
| Operating Cash Flow | 5.83B |
| Capital Expenditures | -2.4B |
| Free Cash Flow | 3.43B |
| FCF Per Share | 0.92 |
Margins
Gross margin is 11.13%, with operating and profit margins of 2.96% and 1.65%.
| Gross Margin | 11.13% |
| Operating Margin | 2.96% |
| Pretax Margin | 2.91% |
| Profit Margin | 1.65% |
| EBITDA Margin | 4.47% |
| EBIT Margin | 2.96% |
| FCF Margin | 1.24% |
Dividends & Yields
SHPMY pays an annual dividend of $0.34, which amounts to a dividend yield of 0.85%.
| Dividend Per Share | $0.34 |
| Dividend Yield | 0.85% |
| Dividend Growth (YoY) | -33.02% |
| Payout Ratio | 40.72% |
| Earnings Yield | 10.09% |
| FCF Yield | 1.52% |
Analyst Forecast
Currently there are no analyst rating for SHPMY.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 1.89 |
| Piotroski F-Score | 6 |